Brokerages predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will announce $1.25 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Aclaris Therapeutics’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $1.40 million. Aclaris Therapeutics posted sales of $5.87 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 78.7%. The company is scheduled to report its next quarterly earnings results on Thursday, August 13th.
On average, analysts expect that Aclaris Therapeutics will report full-year sales of $5.15 million for the current fiscal year, with estimates ranging from $4.72 million to $5.60 million. For the next financial year, analysts forecast that the company will post sales of $5.45 million, with estimates ranging from $4.50 million to $6.80 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter. Aclaris Therapeutics had a negative return on equity of 99.67% and a negative net margin of 1,490.64%. The firm had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $1.27 million.
A number of brokerages recently weighed in on ACRS. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.13.
Shares of Aclaris Therapeutics stock traded down $0.02 on Monday, reaching $1.72. The stock had a trading volume of 68,967 shares, compared to its average volume of 1,047,061. The business’s 50 day moving average is $1.47 and its two-hundred day moving average is $1.40. The company has a market cap of $74.10 million, a P/E ratio of -0.52 and a beta of 1.17. The company has a current ratio of 4.01, a quick ratio of 4.01 and a debt-to-equity ratio of 0.18. Aclaris Therapeutics has a 1 year low of $0.70 and a 1 year high of $2.45.
Hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in shares of Aclaris Therapeutics during the first quarter worth approximately $103,000. Oxford Asset Management LLP purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $52,000. UBS Group AG raised its stake in shares of Aclaris Therapeutics by 317.4% during the fourth quarter. UBS Group AG now owns 37,806 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 28,749 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Aclaris Therapeutics by 100.3% during the first quarter. Wells Fargo & Company MN now owns 52,350 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 26,213 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Aclaris Therapeutics by 16.8% during the first quarter. HighTower Advisors LLC now owns 69,635 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 10,000 shares in the last quarter. 81.27% of the stock is currently owned by hedge funds and other institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Featured Article: What is a death cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.